Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data by Roux, Jonathan et al.
HAL Id: hal-02444012
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02444012
Submitted on 29 Jan 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International
License
Use of healthcare services by patients with multiple
sclerosis in France over 2010-2015: a nationwide
population-based study using health administrative data
Jonathan Roux, Alice Guilleux, Mathilde Lefort, Emmanuelle Leray
To cite this version:
Jonathan Roux, Alice Guilleux, Mathilde Lefort, Emmanuelle Leray. Use of healthcare services by
patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using
health administrative data. Multiple Sclerosis Journal - Experimental, Translational and Clinical,
SAGE Publications, 2019, 5 (4), pp.2055217319896090. ￿10.1177/2055217319896090￿. ￿hal-02444012￿
Original Research Paper
Use of healthcare services by patients with multiple
sclerosis in France over 2010–2015: a nationwide
population-based study using health
administrative data
J. Roux , A. Guilleux, M. Lefort and E. Leray
Abstract
Background: Most of the knowledge about people with multiple sclerosis (PwMS) in France comes
from cohorts, which may suffer from recruitment bias or from the unique registry located in Lorraine,
East France.
Objective: To describe use of care in the French population of PwMS, over 2010–2015.
Methods: All PwMS in the French national health data system (97% of the general population covered)
were included. Demographics, and use of care were described (visits with general practitioners (GPs),
neurologists, nurses, physiotherapists and hospitalisations). A focus on the neurological follow-up was
also conducted.
Results: A total of 112,415 PwMS were identified (sex ratio F:M¼ 2.4, median age 46), of whom 5005
died during follow-up. The median numbers of visits with GPs and neurologists were 6.6 and 1.3
respectively per patient-year. Moreover, 53,457 (47.6%) received multiple sclerosis (MS) treatments;
about 13% of patients had no neurological follow-up, and 81.8% had at least one hospitalisation.
Conclusions: For the first time in France, this exhaustive dataset offered the opportunity to provide
objective figures regarding care practices for MS at the national level, without any selection bias. It also
allowed description of patients with MS according to their neurological follow-up, especially those who
were absent from cohorts led by neurologists.
Keywords: Multiple sclerosis, care-seeking, administrative database, neurologists, hospital admissions,
France
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Introduction
France is a high-prevalence area for multiple sclero-
sis (MS).1 The most recent estimation from 31
December, 2012 was 151.2 per 100,000 inhabitants,
with 99,123 people with MS (PwMS).2 This figure
came from a four-criterion algorithm applied to the
French national health data system (Systeme
National des Donnees de Sante; SNDS),3 and was
used to measure healthcare expenditure related to
MS in France.4 Since 2010, this database has cov-
ered almost 66 million inhabitants (97% estimated
coverage of the general French population), without
any socio-economic or demographic restrictions.3
These individual and longitudinal data are prospec-
tively recorded and exhaustive, offering a great
opportunity for epidemiological studies as a comple-
ment to cohorts, which may only provide a partial
vision of PwMS due to potential recruitment bias.
This database was made possible because of the
French healthcare system, which is a universal
service provided to each citizen irrespective of
wealth, age or social status. It is composed of a
fully integrated network of public hospitals, private
hospitals (also called clinics), healthcare professio-
nals (HCPs) and other medical service providers.
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Primary healthcare is based on a network of private
general practitioners (GPs) that in 2017 had a ratio
of 1 GP per 760 inhabitants.5,6 In addition to primary
care, specialised care is available in both public and
private settings. In 2017, there were 2450 neurolo-
gists in France, amongst whom 67% worked in
public hospitals and 33% worked out-of-hospital
(private practice).5,6 In the last decade, MS expert
centres, Centre de ressources et de competences pour
la sclerose en plaques (CRC SEP), gathering multi-
disciplinary teams including both medical and para-
medical HCPs, have emerged in university public
hospitals (one per region, amounting to 23 for the
whole territory).7 In the French health system, each
medical procedure is paid by the patient and then
reimbursed by health insurance. A specific status,
‘long-term disease’ (LTD), available upon request,
allows for 100% reimbursement of both outpatient
and hospital care for a list of 30 diseases, MS being
one of them.
Studies on care-seeking for MS in France have
focused on an economical perspective, quantifying
MS costs for society,4,8 rather than on the level of
care consumption of PwMS.9 However, describing
the use of care by PwMS, especially the respective
roles of GPs and neurologists, as well as the distinc-
tion between public and private settings, and the
level of hospitalisation related or not to MS would
be helpful to identify inequalities, optimise manage-
ment of MS and define an appropriate care pathway
for this chronic disease. Moreover, as opposed to our
previous study that was based on only a sample of
the French population,9 the SNDS gives access to
the entire French population.
In this context, our main objective was to describe the
level of care-seeking in the exhaustive population of
PwMS in France over the 2010–2015 period using the
French national health data system. A secondary
objective was to describe the demographical and clin-
ical characteristics of this population.
Materials and methods
Data source
Since 2006, the SNDS has compiled all out-of-hospital
reimbursed care consumption (e.g. consultations and
home visits with private HCPs, drugs dispensed, and
paramedical care).3 Regarding consultations and para-
medical care, the date, the specialty of the HCP and
the type of care are available.3,9 Drugs are identified
using CIP13 (Code Identifiant de Presentation), which
is a unique French 13-number identifier for each
presentation of a pharmaceutical medicine.
This dataset is individually linked to in-hospital data
(private and public) from medicine, surgery and
obstetrics wards (MSO) and rehabilitation wards
(REHAB).3 The latter contains the start and end
dates of hospitalisations (including one-day hospital-
isations) and the diagnoses established at discharge
and coded using the International Classification of
Diseases, 10th version (ICD-10).10 Outpatient consul-
tations, that is, consultations held in hospitals, are also
included, and assigned by default to GP when medical
specialty cannot be determined.
Each patient can be identified by their unique ID that
remains with them throughout their lifetime. It
implies that if a patient has emigrated during the
study period and subsequently returned to France,
his/her care consumption could be retrieved and
linked to previous data. However, only a small
amount of information about the patients themselves
is available: gender, birth year, death date, health
insurance scheme (general scheme, agricultural
workers, self-employed workers and other schemes)
and LTD status (according to ICD-10 codes), and its
corresponding starting year, if applicable.3 An indi-
vidual’s CMU (Couverture Maladie Universelle)
status,11 which is the universal health insurance
run by the general scheme, is also available.
The CMU provides access to social protection for
people considered to be on a low income, taking
the number of patients in the household and the
size of the city of residence into consideration.
In addition to this individual-level status, the
socio-economic level of the area of residence for
each patient was estimated using the FDep social
deprivation index,12 which is a variable available
at city level and categorised in quintiles.
Ethical and data access approvals for the present
study were obtained in accordance with French
legislation.
Study population
The following criteria, adapted from the most recent
French MS prevalence study,2 were used to identify
MS cases over the period 2010–2015: (i) at least
one reimbursement for an MS-specific disease-
modifying therapy (DMT) (beta-interferon, glatiramer
acetate, fingolimod, natalizumab, teriflunomide, or
dimethyl fumarate); or (ii) an active LTD for MS;
or (iii) at least one admission in MSO or REHAB
hospitals with a discharge diagnosis of MS, coded
‘G35’. The date of MS identification was defined as
the earliest date between: date of the admission into
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LTD status for MS (potentially anterior to 1 January
2010), the first date of hospitalisation for MS and the
first date of DMT prescription. The study population
was thus formed of prevalent PwMS, that is, cases
present in January 2010 (MS identification date ante-
rior to January 2010), but also of incident cases over
the study period, that is, PwMS who were identified
between 1 January, 2010 and 31 December, 2015.
Therefore, the inclusion date for each PwMS was
defined as 1 January, 2010 for prevalent cases, and
date of MS identification (comprised within 2010–
2015) for incident cases. PwMS were followed up
from their inclusion date until their death or 31
December, 2015. People who had no reimbursement
over the study period were excluded as this probably
corresponded to people who left the covered regimens
or who no longer lived in France. To estimate some
clinical parameters at inclusion, data was extracted
for the years 2009–2015.
Outcomes
The following data was considered: home and out-
patient visits with GPs, neurologists, and paramedi-
cal encounters with nurses and physiotherapists.
Because of uncertainty about the HCP’s specialty
in outpatient visits, those performed in hospitals by
GPs where grouped with the neurologists’ visits.
Hospitalisations in MSO or REHAB wards
were analysed separately. Moreover, the ways in
(hospital, home, emergency) and out (hospital,
home, death) of the MSO ward were quantified.
Hospitalisations corresponding to DMT injections
and sessions were quantified then excluded from
all analyses. All-cause admissions were considered
together first, then separately for MS-related (main
diagnosis ‘G35’) and non-MS-related admissions.
Neurological follow-up was split into four categories:
follow-up with private neurologists only, follow-up
with public neurologists only (performed
in hospitals, including CRC SEP), mixed follow-up
(private and public), and absence of neurological
follow-up. The characteristics of the patients were
presented according to these categories.
Patients were considered treated if they had at least
one prescription dispensed of an MS-specific DMT
over the 2010–2015 study period, that is, beta-
interferon, glatiramer acetate, teriflunomide, fingoli-
mod, natalizumab and dimethyl fumarate. Neither
mitoxantrone, nor cyclophosphamide were available
in the database, as they are not recorded in hospital
data. Initiations of a DMT as well as DMT stops
could occur over the study period. The Charlson
comorbidity index, adapted for French administra-
tive databases,13 was calculated in the year before
the inclusion date amongst people with sufficient
follow-up and then categorised as a four-level
score (0, 1–2, 3–4, 5).
Statistical analysis
An age–sex pyramid was drawn for the study popu-
lation and other characteristics were described using
proportions or medians and the interquartile range.
For each type of care, two kinds of indicators were
computed: the number of visits per patient-year and
the proportion of patients receiving this care at least
once over the study period. In addition, a global
parameter summarising the total number of consulta-
tions and outpatient visits, regardless of the medical
specialty, was computed. Regarding hospitalisations,
the median length of stay was calculated and the most
frequent hospitalisation diagnoses were presented in a
sunburst diagram. The characteristics of PwMS were
compared according to their type of neurological
follow-up. No statistical tests were realised because
of the exhaustiveness of the dataset.
The PwMS who died over the study period were
described and their cause of death was approximated
using the main diagnosis of the hospital stay for
those who died in hospital, and was represented
with a sunburst diagram. A classification proposed
by our team14 was then used to determine whether
death was MS-related.
All analyses were conducted using R (v.3.4.3).15
Results
Characteristics of the population
Overall, 112,415 patients were identified as having MS
in France over the period 2010–2015. The sex ratio F:
M was 2.4 and the median age in 2010 was 46 (36–57).
The age–sex distribution is presented in Figure 1, and
additional characteristics in Table 1. Amongst the
103,455 (92.0%) patients with a Charlson index avail-
able, one-fifth (n¼ 19,818; 19.2%) had at least one
comorbid condition, chronic pulmonary disease being
the most frequent (n¼ 6923; 6.2%). At least one MS
treatment was identified for 53,457 (47.6%) PwMS.
Use of healthcare services
The results show a high use of health resources
(Table 2), with a median number of visits to an HCP
of 16.3 (10.2–26.9) per patient-year. The predominant
place was attributed to GPs with 6.6 (3.7–12.0) visits
per patient-year. Moreover, over the 6 years, 71.2%
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and 75.1% of PwMS had at least one annual visit with
a GP or a neurologist, respectively. Over the study
period, 40,247 (35.7%) PwMS went to a CRC SEP
at least once. The presence of comorbidities was
correlated with increased care-seeking, both medical
and paramedical, and both in and out-of-hospital, as
indicated in Table 2.
Neurological follow-up
About 38% of patients had a mixed neurological
follow-up (private and public), about 32% had a
follow-up with public neurologists only, about
17% had a follow-up with private neurologists
only, while the remaining 13% had an absence of
neurological follow-up (Table 3). Patients without
any neurological follow-up were older and had a
longer disease duration. Moreover, patients followed
up by public neurologists generally lived in the most
deprived areas; conversely, those followed up by
private neurologists lived in some of the most
wealthiest areas. We also noted that 3119 patients
(5.8% of treated patients) did not visit a neurologist
but were treated, even though DMTs can only be
prescribed by this medical specialty.
Hospital stays
On the whole, 1,002,809 hospital admissions in
MSO were extracted for 2010–2015. Injections of
a DMT for MS (461,595; 46.0%) were excluded
first, of which 249,816 (54.1%) were natalizumab
injections (in 7529 patients); the remainder
(211,779; 45.9%) were unspecified but were
probably corticosteroid injections or mitoxantrone
infusions. Secondly, 109,973 (11.0%) hospital
stays were excluded because they corresponded to
recurring therapeutic sessions outside MS (such as
dialysis or cancer chemotherapy). After these exclu-
sions (431,241 hospitalisations remaining), a large
proportion of hospitalisations was not related to
MS (310,225; 71.9%). The top 10 ICD-10 hospital-
isations are presented in Figure 2. Moreover, we
found a lower proportion of admissions through
the emergency ward in MS-related than in non-
MS-related admissions (9.1% versus 22.0%) (see
Figure S1 in supplementary material). Deaths
occurred more frequently during non-MS-related
(0.8%) than in MS-related admissions (0.2%).
Deaths
Over the 6-year study period, 5005 deaths occurred.
As summarised in Table 1, the median age at death
was 67.0 and almost half (43.5%) had a Charlson
index score equal to or greater than 1, which is much
higher than in the total population (19.2%).
The association between the Charlson index score
and the probability of dying was illustrated through
Figure 1. Age–sex pyramid of patients with MS in France identified over 2010–2015 (N¼ 112,415).
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Table 1. Characteristics of the 112,415 patients with MS and of the 5005 deaths observed over the 2010–2015 study
period.
Overall population (N¼ 112,415)
Women, n (%) 79,735 (70.9%)
Year of birth* 1964 (1953–1974)
Age at MS identification* (years) 40 (31–50)
Approximated MS duration at inclusion*,a (years) 2.5 (0.0–9.8)
Study follow-up duration*,b (years) 6.0 (3.9–6.0)
Deaths, n (%) 5005 (4.5%)
Health insurance scheme, n (%)
General scheme excluding CMU beneficiaries 98,359 (87.5%)
Agricultural workers 4148 (3.7%)
Self-employed workers 4242 (3.8%)
CMU beneficiaries 4258 (3.8%)
Other schemes 1408 (1.3%)
Charlson comorbidity indexc, n (%)
Missing 8960 (8.0%)
0 83,637 (74.4%)
1–2 17,159 (15.3%)
3–4 2156 (1.9%)
5 503 (0.4%)
Deprivation index of the city of residence in 2009, n (%)
Missing 1520 (1.4%)
1st quintile (most favoured) 21,422 (19.1%)
2nd quintile 22,193 (19.7%)
3rd quintile 22,318 (19.9%)
4th quintile 22,479 (20.0%)
5th quintile (most deprived) 22,483 (20.0%)
Patients dying over the study period (n ¼ 5005)
Women, n (%) 3057 (61.1%)
Age at death* (years) 67.0 (58.0–78.0)
Age at MS identification* (years) 53.0 (42.0–65.0)
Time from LTD admission* (n¼ 3711) (years) 14.0 (7.0–21.0)
Charlson comorbidity indexc, n (%)
Missing 209 (4.2%)
0 2708 (54.1%)
1–2 1523 (30.4%)
3–4 396 (7.9%)
5 169 (3.4%)
Place of death, n (%)
Unknown 93 (1.9%)
At hospital 3102 (62.0%)
At home 1903 (38.0%)
Cause of death of patients dying at hospital (N¼ 3102)d, n (%)
MS-related 1025 (33.0%)
Non-MS-related 2077 (67.0%)
Total number of access to care in the previous year
All medical specialties (private or public)* 14.0 (7.0–22.0)
Of whom visits to GP* 10.0 (4.0–16.0)
At least one hospitalisation in MSO, n (%)
All diagnoses 4263 (85.2%)
MS-related 716 (14.3%)
(continued)
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Table 2. Care-seeking of the MS population over the 2010–2015 period (N¼ 112,415) and according to the Charlson comorbidity
index (data missing for 8960 patients).
Total
N¼ 112,415
Charlson index <3
n ¼ 100,796
Charlson index 3
n¼ 2659
At least one visit to, n (%)
GP 109,963 (97.8%) 99,341 (98.6%) 2616 (98.4%)
Private neurologist 62,097 (55.2%) 56,912 (56.5%) 1096 (41.2%)
Public neurologista 78,367 (69.7%) 70,538 (70.0%) 1989 (74.8%)
Private or public neurologista 98,058 (87.2%) 88,582 (87.9%) 2225 (83.7%)
Nurse 94,664 (84.2%) 86,420 (85.7%) 2437 (91.7%)
Physiotherapist 61,332 (54.6%) 56,633 (56.2%) 1952 (73.4%)
Number of visits per patient-year
GP* 6.6 (3.7–12.0) 6.8 (3.8–12.2) 11.0 (6.2–20.2)
Private neurologist* 0.2 (0.0–1.7) 0.2 (0.0–1.7) 0.0 (0.0–0.7)
Public neurologist*,a 0.4 (0.0–1.2) 0.3 (0.0–1.2) 0.5 (0.0–1.4)
Private or public neurologist*,a 1.3 (0.4–2.7) 1.3 (0.4–2.7) 1.0 (0.3–2.4)
Nurse* 3.3 (0.5–14.2) 3.5 (0.7–14.8) 16.9 (3.2–128.3)
Physiotherapist* 1.3 (0.0–26.5) 1.7 (0.0–28.5) 14.3 (0.0–73.9)
All medical specialties (private or public)* 16.3 (10.2–26.9) 16.8 (10.8–27.2) 25.7 (15.9–44.9)
At least one hospitalisation in MSO, n (%)
All diagnoses 92,007 (81.8%) 82,548 (81.9%) 2537 (95.3%)
MS-related 44,125 (39.3%) 39,364 (39.1%) 873 (32.8%)
Length of stay in MSOb (days per patient-year)
All diagnoses* 2.3 (0.8–5.9) 2.2 (0.8–5.7) 8.7 (3.2–23.6)
MS-related* 1.1 (0.5–2.5) 1.1 (0.5–2.5) 1.5 (0.6–3.7)
At least one hospitalisation in REHAB, n (%)
All diagnoses 27,236 (24.2%) 24,801 (24.6%) 1213 (45.6%)
MS-related 20,117 (17.9%) 18,664 (18.5%) 558 (21.0%)
Length of stay in REHABb (days per patient-year)
All diagnoses* 7.7 (3.2–17.8) 7.3 (3.2–17.3) 13.0 (5.2–31.7)
MS-related* 6.3 (2.7–14.7) 6.3 (2.5–14.5) 8.2 (3.8–18.0)
Received MS-specific DMT at least once, n (%) 53,455 (46.7%) 48,440 (48.1%) 520 (19.6%)
Charlson comorbidity index <3 and 3 correspond to the PwMS having a Charlson index based on data from the 12 months preceding their
entry in the study, if available, strictly lower than 3 or greater than 3, respectively.
MS¼multiple sclerosis; GP¼ general practitioner; MSO¼medicine, surgery or obstetrics; REHAB¼ rehabilitation.
*Median (q1–q3). aPublic neurologists and public GPs altogether; bonly for patients having at least one hospitalization.
Table 1. Continued.
Length of stay in MSOe (days)
All diagnoses* 21.0 (8.0–43.0)
MS-related* 7.0 (2.0–19.0)
MS¼multiple sclerosis; CMU¼ universal health insurance (Couverture Maladie Universelle); GP¼ general practitioner;
MSO¼medicine, surgery or obstetrics.
*Median (q1–q3). aTime from MS identification until inclusion date; btime from inclusion date until end of follow-up; cbased on
data from the 12 months preceding study entry if available; daccording to the algorithm presented in Kingwell et al.14; eonly for
patients having at least one hospitalisation.
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Kaplan–Meier curves (Figure 3). Care-seeking with
GPs represented the most important part of consul-
tations in the year prior to death (75.0% in median)
and most hospitalisations were unrelated to MS.
Causes of death were summarised using a sunburst
diagram (Figure 2). The most common causes of
death were diseases of the respiratory system
(24.0%), and neoplasms including cancers, represent-
ing 18.2% of deaths. About one-third of in-hospital
deaths could be considered as MS-related.
Discussion
To our knowledge, this is the first study conducted
on the entire population of PwMS in France that
provides a precise description of this population
and an overview of care practices for MS at national
level. The previous studies came either from the
French health insurance system restricted to salaried
workers,2,4 or from the French Observatory for MS
(OFSEP; Observatoire Franc¸ais de la Sclerose En
Plaques)16 in which data collection is mainly based
upon the CRC SEP or from the Lorraine registry.17–
19 The use of SNDS allowed access to patients with-
out any neurological follow-up or followed exclu-
sively in private settings, which represented 14,357
patients (12.8%) and 19,691 (17.5%), respectively.
We found a notable level of visits to HCPs with 16.3
consultations per patient-year, significantly higher
than the 6.5 visits per year reported in the French
general population.20 These observations are in accor-
dance with previous French9 and Canadian21,22 stud-
ies showing a higher level of care-seeking in PwMS
compared with the general population. In the present
study, GPs were the most frequently visited HCPs
with a median of 6.6 consultations per patient-year.
Table 3. Comparison of patient characteristics according to the type of neurological follow-up (N¼ 112,415).
Private only Public only Mixed Absence
19,691 (17.5%) 35,961 (32.0%) 42,406 (37.7%) 14,357 (12.8%)
Women, n (%) 14,509 (73.7%) 24,591 (68.4%) 30,596 (72.2%) 10,039 (69.9%)
Age at MS identification* (years) 41 (33–50) 40 (31–50) 39 (30–48) 44 (34–55)
Year of birth* 1963 (1954–1972) 1964 (1953–1975) 1966 (1956–1976) 1957 (1946–1968)
Approximated MS duration
at inclusion*,a (years)
3.2 (0.0–9.6) 2.3 (0.0–10.1) 1.5 (0.0–8.4) 5.7 (0.0–13.6)
Study follow-up duration*,b (years) 6.0 (4.3–6.0) 6.0 (3.8–6.0) 6.0 (3.8–6.0) 6.0 (4.0–6.0)
Received MS-specific DMT
at least once, n (%)
10,866 (55.2%) 15,157 (42.1%) 24,313 (57.3%) 3119 (21.7%)
Health insurance scheme, n (%)
General scheme excluding
CMU beneficiaries
17,401 (88.4%) 30,930 (86.0%) 37,531 (88.5%) 12,497 (87.0%)
Agricultural workers 786 (4.0%) 1492 (4.1%) 1242 (2.9%) 628 (4.4%)
Self-employed workers 778 (3.9%) 1618 (4.5%) 1258 (3.0%) 588 (4.1%)
CMU beneficiaries 540 (2.7%) 1336 (3.7%) 1964 (4.6%) 418 (2.9%)
Other schemes 186 (0.9%) 585 (1.6%) 411 (1.0%) 226 (1.6%)
Charlson comorbidity indexc, n (%)
Missing 1411 (7.2%) 3162 (8.8%) 2678 (6.3%) 1709 (11.9%)
0 15,664 (79.5%) 25,558 (71.1%) 32,464 (76.6%) 9951 (69.3%)
1–2 2380 (12.1%) 6139 (17.1%) 6404 (15.1%) 2263 (15.8%)
3–4 193 (1.0%) 893 (2.5%) 728 (1.7%) 342 (2.4%)
5 43 (0.2%) 236 (0.7%) 132 (0.3%) 92 (0.6%)
Visits to GP per patient-year* 5.7 (3.2–10.1) 6.7 (3.5–12.2) 7.5 (4.3–13.1) 5.2 (2.3–10.5)
Visits to neurologists per patient-year*,d 1.9 (0.7–3.0) 0.8 (0.3–1.7) 2.4 (1.4–3.8) –
All medical specialties per patient-year*
(private or public)
15.2 (9.8–24.0) 15.7 (9.7–26.2) 19.0 (12.5–30.4) 11.7 (6.3–20.8)
MS¼multiple sclerosis; CMU¼ universal health insurance (Couverture Maladie Universelle); DMT¼ disease-modifying therapy;
GP¼ general practitioner.
*Median (q1–q3). aTime from MS identification until inclusion date; btime from inclusion date until end of follow-up; cbased on data from the
12 months preceding study entry, if available; dprivate and public neurologists, or public GPs.
Roux et al.
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This central role is in line with the fact that MS is a
chronic disease with many different symptoms and
has an impact on daily life. Moreover, MS is fre-
quently associated with comorbid conditions, which
are more prevalent than in the general population23
and their prevalence increases care consumption,24,25
as confirmed in the present study by the annual
number of visits with GPs increasing to 11.0.
One-third of PwMS were identified as having at least
one visit to a CRC SEP during the study period,
which corresponded with a previous French
study.19 This result highlights the risk of recruitment
bias in hospital-based databases, favouring active or
severe MS and people with a high level of care-
seeking19,26 or more complicated needs.19,26
Concerning hospitalisations, the low number of
admissions through the emergency ward (9.1%)
probably reflects that the majority of MS-related
admissions were planned; the emergency entrances
were likely to be related to episodes of relapse or
disease worsening. Regarding mortality data,
MS was the principal cause of death in 9.5% of
in-hospital deaths, which also corresponds with the
results from the literature.27 However, this result is
Figure 2. Diagnoses related to (a) hospitalisations in MSO ward (except sessions and treatment injections) (N¼ 431,610)
and (b) hospitalisations ending in death (n ¼ 5005) over the 2010-2015 period.
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probably underestimated since the cause of death
was missing for one-third of the population, that is,
the ones dying out-of-hospital. We did not find any
specific distribution of MS in the five categories of
the social deprivation index.
Neurological follow-up appeared to be mainly
mixed and public, which is not surprising as there
are twice as many neurologists in public hospitals
than in private offices28 and due to the fact that CRC
SEP are located in university hospitals. Because the
medical specialty is not always mentioned in hospi-
tal data, we have considered hospital visits to GPs as
visits to public neurologists. This strong assumption
may thus lead to an overestimation of the level of
care consumption with neurologists, but we do think
that it may introduce a smaller bias than excluding
all the outpatient visits with GPs. Indeed, in France,
most of the MS expert neurologists are based in
hospitals and account for a large part of care of
PwMS.7 We also found that about 13% of patients
had no neurological follow-up at all over the 6-year
study period. In our opinion, this figure is plausible
as it may correspond to several categories of patient:
people with evolved MS, that is, highly disabled;
elderly people living in nursing homes; and those
who are mainly followed by GPs and symptom spe-
cialists. An unexpected result was the percentage of
patients in this group receiving DMT; this may
reflect either data entry errors or misuse of medica-
tions. Ongoing work is being carried out on the use
of DMTs, with the aim of exploring therapeutic
sequences over time and evaluating the impact of
the arrival of new drugs on the market.
The use of the SNDS offered us the opportunity to
describe the nearly exhaustive population of PwMS
living in France. Indeed, 97% of the general French
population is covered,3 which means that no selection
or recruitment bias is anticipated, as already men-
tioned. This represents a significant advantage over
other health insurance systems, such as those in the
United States (Medicaid, Medicare), and over other
French MS data sources, such as the OFSEP cohort.
The latter is a network of French expert centres that in
2016 had an estimated MS patient coverage of 46.3%
[44.8–47.8]29 and is not therefore considered to
reflect the variety of French care practices.
Moreover, administrative data are automatically and
systematically collected in the SNDS, and therefore,
not dependent from the completion of a database by
neurologists or research assistants. This system thus
drives the risk of having missing data close to zero.
However, no clinical data are available in the SNDS
as it is primarily an economic database. For instance,
we did not have the date of MS onset, MS clinical
form, relapse occurrence, or the disability level; data
that is reliably available in the OFSEP database.16
Finally, complex administrative data need significant
expertise and the use of several hypotheses to build
the appropriate epidemiological indicators.
Due to the absence of neurologist-based data collec-
tion, there is a risk of false-positive cases in the
Figure 3. Survival according to the Charlson comorbidity index (N ¼ 112,415).
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dataset, that is, people being misclassified as PwMS.
Indeed, we used an algorithm previously developed
in France,2 but which has not yet been validated.
Overall, 26.7% of the PwMS population was iden-
tified using a single source. In our opinion, LTD
status and DMT prescription are robust criteria, but
the criterion based on hospitalisations may raise
issues due to the risk of errors in data entry, and
the risk of a suspected MS diagnosis that is not con-
firmed later in the patient’s history. This may apply
especially to patients with only one hospitalisation
(7586 cases; 6.7%). Nonetheless, regarding case
ascertainment, the risk of false negatives, that is,
of MS patients not having been identified, is very
low; indeed, this would mean that they did not use
any care related to MS for more than six consecutive
years, which seems highly improbable. For this
reason, we chose to exclude people that had no
care consumption over the study period (391 cases;
0.3%), which may have corresponded to people who
were not covered by health insurance or to benign
MS or misdiagnosis.
To conclude, the present study confirms that the
SNDS is a useful data source for epidemiological
and public health purposes. It is one of the largest
datasets of MS worldwide. However, given its afore-
mentioned limitations, our intention is now to
link this dataset to the OFSEP cohort to combine
the respective advantages of both data sources.
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